Don't tell nuclear medicine vendorTrionix that you can't fight the Radiological Society of NorthAmerica. The Twinsburg, OH, company is returning to the RSNA'stechnical exhibit after sitting out last year because of a disputewith the meeting's organizers
Don't tell nuclear medicine vendorTrionix that you can't fight the Radiological Society of NorthAmerica. The Twinsburg, OH, company is returning to the RSNA'stechnical exhibit after sitting out last year because of a disputewith the meeting's organizers over its booth location.
Trionix suffered through the 1992 and 1991 meetings with abooth located in the nether regions of the exhibit hall, nearthe entrance area for mobile trucks in the back of the hall. RSNAorganizers tried to assign the vendor the same spot for last year'smeeting, but the company balked. When the RSNA refused to giveTrionix a new location the company pulled out of the meeting,according to president Chun Bin Lim (SCAN 10/6/93).
This year, the society was more accommodating and gave Trionixa space closer to the central area of the technical exhibit floor.The company's return to the exhibit was also influenced by a strategicdecision to place more emphasis on U.S. sales and marketing. Trionixspent much of last year targeting international sales of its gammacameras.
At next week's meeting, Trionix will showcase its Triad XLT20, a triple-head gamma camera with larger detectors than theTriad XLT. Each detector on the Triad XLT 20 has a 20 x 15-inchfield-of-view, making it optimal for whole-body studies. Trionixunveiled the camera at this year's Society of Nuclear Medicinemeeting in Orlando (SCAN 6/29/94). At the RSNA conference, Trionixwill display for the first time the results of clinical studiesusing the camera, which has Food and Drug Administration 510(k)clearance.
Trionix will also feature its latest work in 511-KeV imagingusing high-energy collimators, as well as the Biad XLT and TriadXLT gamma cameras.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.